<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973933</url>
  </required_header>
  <id_info>
    <org_study_id>MPI02</org_study_id>
    <nct_id>NCT01973933</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR</brief_title>
  <official_title>A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Pyrimethamine and Metformin IR After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of
      pyrimethamine and metformin IR after oral administration in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(area under the plasma concentration-time curve)</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12h postdose</time_frame>
    <description>AUC(area under the plasma concentration-time curve), Cmax(maximum plasma concentration), t1/2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUG(total area under the serum concentration-time curve for glucose)</measure>
    <time_frame>predose and 15, 30, 45, 60, 90, 120, 150, 180min oral glucose tolerance test</time_frame>
    <description>AUG (total area under the serum concentration-time curve for glucose) Gmax(maximum serum glucose concentration)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Metformin and Pyrimethamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 750mg(D1), Metformin 500mg(D2)/Metformin 750mg+Pyrimethamine 50mg(D7), Metformin 500mg+Pyrimethamine 50mg(D8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Pyrimethamine</intervention_name>
    <arm_group_label>Metformin and Pyrimethamine</arm_group_label>
    <other_name>Diabex</other_name>
    <other_name>Daraprim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male subject aged 20 to 45 at screening A body weight in the range of 50 kg
             (inclusive)

          -  100 kg (inclusive) with ideal body weight range of +- 25% subjects who decide to
             participate voluntarily and write a informed consent form

        Exclusion Criteria:

          -  subjects who have clinically significant disease of cardiovascular, respiratory,
             renal, endocrinological, hematological, gastrointestinal, neurological(central nervous
             system), psychiatric disorders or malignant tumor

          -  Subject judged not eligible for study participation by investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Yong Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>October 27, 2013</last_update_submitted>
  <last_update_submitted_qc>October 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Jae Yong Chung</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Pyrimethamine</keyword>
  <keyword>Drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

